{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T03:42:59Z","timestamp":1794541379661,"version":"4.9.1"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100002360","name":"CAS | Beijing Institute of Genomics, Chinese Academy of Sciences","doi-asserted-by":"publisher","award":["XDA0460403"],"award-info":[{"award-number":["XDA0460403"]}],"id":[{"id":"10.13039\/501100002360","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81970175"],"award-info":[{"award-number":["81970175"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82200189"],"award-info":[{"award-number":["82200189"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1038\/s41375-026-02978-3","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T10:51:01Z","timestamp":1780051861000},"page":"1608-1623","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Unraveling cellular and molecular mechanisms of relapse in CD19\/CD22 dual-targeting chimeric antigen receptor T-cell therapy for B-cell acute lymphoblastic leukemia"],"prefix":"10.1038","volume":"40","author":[{"given":"Jiaqi","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3176-8309","authenticated-orcid":false,"given":"Fuhong","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6516-4095","authenticated-orcid":false,"given":"Haiyang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8718-6634","authenticated-orcid":false,"given":"Wenyue","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingxing","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8370-3232","authenticated-orcid":false,"given":"Liang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1332-9230","authenticated-orcid":false,"given":"Jianfeng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0086-2626","authenticated-orcid":false,"given":"Qian-Fei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"2978_CR1","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMra1706169","volume":"379","author":"CH June","year":"2018","unstructured":"June CH, Sadelain M. Chimeric antigen receptor therapy. N Engl J Med. 2018;379:64\u201373.","journal-title":"N Engl J Med"},{"key":"2978_CR2","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41392-023-01708-w","volume":"8","author":"Y Zhai","year":"2023","unstructured":"Zhai Y, Du Y, Li G, Yu M, Hu H, Pan C, et al. Trogocytosis of CAR molecule regulates CAR-T cell dysfunction and tumor antigen escape. Signal Transduct Target Ther. 2023;8:457.","journal-title":"Signal Transduct Target Ther"},{"key":"2978_CR3","doi-asserted-by":"publisher","first-page":"239","DOI":"10.3389\/fimmu.2018.00239","volume":"9","author":"C Tomuleasa","year":"2018","unstructured":"Tomuleasa C, Fuji S, Berce C, Onaciu A, Chira S, Petrushev B, et al. Chimeric antigen receptor T-cells for the treatment of B-cell acute lymphoblastic leukemia. Front Immunol. 2018;9:239.","journal-title":"Front Immunol"},{"key":"2978_CR4","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1182\/blood.2019000017","volume":"135","author":"N Wang","year":"2020","unstructured":"Wang N, Hu X, Cao W, Li C, Xiao Y, Cao Y, et al. Efficacy and safety of CAR19\/22 T-cell cocktail therapy in patients with refractory\/relapsed B-cell malignancies. Blood. 2020;135:17\u201327.","journal-title":"Blood"},{"key":"2978_CR5","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1038\/s41591-021-01436-0","volume":"27","author":"JY Spiegel","year":"2021","unstructured":"Spiegel JY, Patel S, Muffly L, Hossain NM, Oak J, Baird JH, et al. CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. Nat Med. 2021;27:1419\u201331.","journal-title":"Nat Med"},{"key":"2978_CR6","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1038\/s41591-021-01497-1","volume":"27","author":"S Cordoba","year":"2021","unstructured":"Cordoba S, Onuoha S, Thomas S, Pignataro DS, Hough R, Ghorashian S, et al. CAR T\u2009cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B\u2009cell acute lymphoblastic leukemia: a phase 1 trial. Nat Med. 2021;27:1797\u2013805.","journal-title":"Nat Med"},{"key":"2978_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1178403","volume":"14","author":"NJ Fergusson","year":"2023","unstructured":"Fergusson NJ, Adeel K, Kekre N, Atkins H, Hay KA. A systematic review and meta-analysis of CD22 CAR T-cells alone or in combination with CD19 CAR T-cells. Front Immunol. 2023;14:1178403.","journal-title":"Front Immunol"},{"key":"2978_CR8","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1200\/JCO.22.01214","volume":"41","author":"T Wang","year":"2023","unstructured":"Wang T, Tang Y, Cai J, Wan X, Hu S, Lu X, et al. Coadministration of CD19- and CD22-directed chimeric antigen receptor T-cell therapy in childhood B-cell acute lymphoblastic leukemia: a single-arm, multicenter, phase II trial. J Clin Oncol. 2023;41:1670\u201383.","journal-title":"J Clin Oncol"},{"key":"2978_CR9","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1007\/s00262-023-03418-2","volume":"72","author":"J Jin","year":"2023","unstructured":"Jin J, Liu T, Cheng J, Meng J, Wang N, Huang L, et al. MIP3\u03b1 as an early prognostic predictor for patients with B-cell malignancies receiving CD19\/CD22-redirected CAR-T cell cocktail therapy. Cancer Immunol Immunother. 2023;72:2245\u201356.","journal-title":"Cancer Immunol Immunother"},{"key":"2978_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00819-5","volume":"13","author":"S Liu","year":"2023","unstructured":"Liu S, Zhang X, Dai H, Cui W, Yin J, Li Z, et al. Which one is better for refractory\/relapsed acute B-cell lymphoblastic leukemia: Single-target (CD19) or dual-target (tandem or sequential CD19\/CD22) CAR T-cell therapy? Blood cancer J. 2023;13:60.","journal-title":"Blood cancer J"},{"key":"2978_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.884782","volume":"12","author":"Y Zhao","year":"2022","unstructured":"Zhao Y, Zhang J, Yang J, Wu H, Chen Y, Li N, et al. Long-term safety and efficacy of CD19 humanized selective CAR-T therapy in B-ALL patients who have previously received murine-based CD19 CAR-T therapy. Front Oncol. 2022;12:884782.","journal-title":"Front Oncol"},{"key":"2978_CR12","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1007\/s00277-021-04451-w","volume":"100","author":"L Hu","year":"2021","unstructured":"Hu L, Charwudzi A, Li Q, Zhu W, Tao Q, Xiong S, et al. Anti-CD19 CAR-T cell therapy bridge to HSCT decreases the relapse rate and improves the long-term survival of R\/R B-ALL patients: a systematic review and meta-analysis. Ann Hematol. 2021;100:1003\u201312.","journal-title":"Ann Hematol"},{"key":"2978_CR13","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1038\/s41591-018-0146-z","volume":"24","author":"EJ Orlando","year":"2018","unstructured":"Orlando EJ, Han X, Tribouley C, Wood PA, Leary RJ, Riester M, et al. Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia. Nat Med. 2018;24:1504\u20136.","journal-title":"Nat Med"},{"key":"2978_CR14","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","volume":"5","author":"E Sotillo","year":"2015","unstructured":"Sotillo E, Barrett DM, Black KL, Bagashev A, Oldridge D, Wu G, et al. Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov. 2015;5:1282\u201395.","journal-title":"Cancer Discov"},{"key":"2978_CR15","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.3389\/fonc.2019.01237","volume":"9","author":"J Cheng","year":"2019","unstructured":"Cheng J, Zhao L, Zhang Y, Qin Y, Guan Y, Zhang T, et al. Understanding the mechanisms of resistance to CAR T-cell therapy in malignancies. Front Oncol. 2019;9:1237.","journal-title":"Front Oncol"},{"key":"2978_CR16","doi-asserted-by":"crossref","unstructured":"Song MK, Park BB, Uhm JE. Resistance mechanisms to CAR T-cell therapy and overcoming strategy in B-cell hematologic malignancies. Int J Mol Sci. 2019;20:5010.","DOI":"10.3390\/ijms20205010"},{"key":"2978_CR17","doi-asserted-by":"crossref","unstructured":"Majzner RG, Frank MJ, Mount C, Tousley A, Kurtz DM, Sworder B, et al. CD58 aberrations limit durable responses to CD19 CAR in large B cell lymphoma patients treated with axicabtagene ciloleucel but can be overcome through novel CAR engineering. Blood. 2020;136:53\u20134.","DOI":"10.1182\/blood-2020-139605"},{"key":"2978_CR18","doi-asserted-by":"publisher","first-page":"5844","DOI":"10.1182\/bloodadvances.2022007891","volume":"6","author":"X Yan","year":"2022","unstructured":"Yan X, Chen D, Ma X, Wang Y, Guo Y, Wei J, et al. CD58 loss in tumor cells confers functional impairment of CAR T cells. Blood Adv. 2022;6:5844\u201356.","journal-title":"Blood Adv"},{"key":"2978_CR19","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41568-020-00323-z","volume":"21","author":"RC Larson","year":"2021","unstructured":"Larson RC, Maus MV. Recent advances and discoveries in the mechanisms and functions of CAR T cells. Nat Rev Cancer. 2021;21:145\u201361.","journal-title":"Nat Rev Cancer"},{"key":"2978_CR20","doi-asserted-by":"crossref","unstructured":"Beider K, Itzhaki O, Schachter J, Grushchenko-Polaq AH, Voevoda-Dimenshtein V, Rosenberg E, et al. Molecular and functional signatures associated with CAR T cell exhaustion and impaired clinical response in patients with B cell malignancies. Cells. 2022;11:1140.","DOI":"10.3390\/cells11071140"},{"key":"2978_CR21","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nm.4441","volume":"24","author":"TJ Fry","year":"2018","unstructured":"Fry TJ, Shah NN, Orentas RJ, Stetler-Stevenson M, Yuan CM, Ramakrishna S, et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat Med. 2018;24:20\u20138.","journal-title":"Nat Med"},{"key":"2978_CR22","doi-asserted-by":"crossref","unstructured":"He F, Zhang Z, Fang X, Wang QF. Biomedical big data and artificial intelligence in blood. Genom Proteom Bioinform 2025;23:qzaf043.","DOI":"10.1093\/gpbjnl\/qzaf043"},{"key":"2978_CR23","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1089\/ten.tec.2012.0150","volume":"19","author":"LY Chan","year":"2013","unstructured":"Chan LY, Yim EK, Choo AB. Normalized median fluorescence: an alternative flow cytometry analysis method for tracking human embryonic stem cell states during differentiation. Tissue Eng Part C Methods. 2013;19:156\u201365.","journal-title":"Tissue Eng Part C Methods"},{"key":"2978_CR24","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/s41375-018-0180-3","volume":"33","author":"S Haubner","year":"2019","unstructured":"Haubner S, Perna F, K\u00f6hnke T, Schmidt C, Berman S, Augsberger C, et al. Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML. Leukemia. 2019;33:64\u201374.","journal-title":"Leukemia"},{"key":"2978_CR25","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.mam.2005.12.007","volume":"27","author":"M Kubista","year":"2006","unstructured":"Kubista M, Andrade JM, Bengtsson M, Forootan A, Jon\u00e1k J, Lind K, et al. The real-time polymerase chain reaction. Mol Asp Med. 2006;27:95\u2013125.","journal-title":"Mol Asp Med"},{"key":"2978_CR26","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.gpb.2018.12.008","volume":"17","author":"Q Zhang","year":"2019","unstructured":"Zhang Q, Hu H, Chen SY, Liu CJ, Hu FF, Yu J, et al. Transcriptome and regulatory network analyses of CD19-CAR-T immunotherapy for B-ALL. Genomics Proteomics Bioinformatics. 2019;17:190\u2013200.","journal-title":"Genomics Proteomics Bioinformatics"},{"key":"2978_CR27","doi-asserted-by":"publisher","first-page":"e1003665","DOI":"10.1371\/journal.pcbi.1003665","volume":"10","author":"CA Miller","year":"2014","unstructured":"Miller CA, White BS, Dees ND, Griffith M, Welch JS, Griffith OL, et al. SciClone: inferring clonal architecture and tracking the spatial and temporal patterns of tumor evolution. PLoS Comput Biol. 2014;10:e1003665.","journal-title":"PLoS Comput Biol"},{"key":"2978_CR28","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1038\/nprot.2013.143","volume":"8","author":"FA Ran","year":"2013","unstructured":"Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F. Genome engineering using the CRISPR-Cas9 system. Nat Protoc. 2013;8:2281\u2013308.","journal-title":"Nat Protoc"},{"key":"2978_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-40786-1","volume":"9","author":"MP Schroeder","year":"2019","unstructured":"Schroeder MP, Bastian L, Eckert C, G\u00f6kbuget N, James AR, Tanchez JO, et al. Integrated analysis of relapsed B-cell precursor acute lymphoblastic leukemia identifies subtype-specific cytokine and metabolic signatures. Sci Rep. 2019;9:4188.","journal-title":"Sci Rep"},{"key":"2978_CR30","doi-asserted-by":"publisher","first-page":"e1008280","DOI":"10.1371\/journal.pgen.1008280","volume":"15","author":"K Okuyama","year":"2019","unstructured":"Okuyama K, Strid T, Kuruvilla J, Somasundaram R, Cristobal S, Smith E, et al. PAX5 is part of a functional transcription factor network targeted in lymphoid leukemia. PLoS Genet. 2019;15:e1008280.","journal-title":"PLoS Genet"},{"key":"2978_CR31","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.add6403","volume":"8","author":"Y Li","year":"2022","unstructured":"Li Y, Moriyama T, Yoshimura S, Zhao X, Li Z, Yang X, et al. PAX5 epigenetically orchestrates CD58 transcription and modulates blinatumomab response in acute lymphoblastic leukemia. Sci Adv. 2022;8:eadd6403.","journal-title":"Sci Adv"},{"key":"2978_CR32","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/s41586-020-2493-4","volume":"583","author":"JE Moore","year":"2020","unstructured":"Moore JE, Purcaro MJ, Pratt HE, Epstein CB, Shoresh N, Adrian J, et al. Expanded encyclopaedias of DNA elements in the human and mouse genomes. Nature. 2020;583:699\u2013710.","journal-title":"Nature"},{"key":"2978_CR33","doi-asserted-by":"crossref","unstructured":"Stengel A, Schnittger S, Weissmann S, Kuznia S, Kern W, Kohlmann A, et al. TP53 mutations occur in 15.7% of ALL and are associated with MYC-rearrangement, low hypodiploidy, and a poor prognosis. Blood. 2014;124:251\u20138%.","DOI":"10.1182\/blood-2014-02-558833"},{"key":"2978_CR34","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1038\/s41375-018-0073-5","volume":"32","author":"A Hn\u00edzda","year":"2018","unstructured":"Hn\u00edzda A, F\u00e1bry M, Moriyama T, Pachl P, Kugler M, Brinsa V, et al. Relapsed acute lymphoblastic leukemia-specific mutations in NT5C2 cluster into hotspots driving intersubunit stimulation. Leukemia. 2018;32:1393\u2013403.","journal-title":"Leukemia"},{"key":"2978_CR35","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/nm.3078","volume":"19","author":"G Tzoneva","year":"2013","unstructured":"Tzoneva G, Perez-Garcia A, Carpenter Z, Khiabanian H, Tosello V, Allegretta M, et al. Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL. Nat Med. 2013;19:368\u201371.","journal-title":"Nat Med"},{"key":"2978_CR36","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1038\/s41588-022-01159-z","volume":"54","author":"SW Brady","year":"2022","unstructured":"Brady SW, Roberts KG, Gu Z, Shi L, Pounds S, Pei D, et al. The genomic landscape of pediatric acute lymphoblastic leukemia. Nat Genet. 2022;54:1376\u201389.","journal-title":"Nat Genet"},{"key":"2978_CR37","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1182\/blood.2019003293","volume":"135","author":"J Pan","year":"2020","unstructured":"Pan J, Zuo S, Deng B, Xu X, Li C, Zheng Q, et al. Sequential CD19-22 CAR T therapy induces sustained remission in children with r\/r B-ALL. Blood. 2020;135:387\u201391.","journal-title":"Blood"},{"key":"2978_CR38","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1182\/blood.2022015795","volume":"140","author":"H Shalabi","year":"2022","unstructured":"Shalabi H, Qin H, Su A, Yates B, Wolters PL, Steinberg SM, et al. CD19\/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR. Blood. 2022;140:451\u201363.","journal-title":"Blood"},{"key":"2978_CR39","doi-asserted-by":"crossref","unstructured":"Yang X, Wei J, Zhou J. Overcoming resistance to anti-CD19 CAR T-cell therapy in B-cell malignancies. Hematol Oncol. 2022;40:821\u201334.","DOI":"10.1002\/hon.3036"},{"key":"2978_CR40","doi-asserted-by":"publisher","first-page":"2664","DOI":"10.3389\/fimmu.2019.02664","volume":"10","author":"X Xu","year":"2019","unstructured":"Xu X, Sun Q, Liang X, Chen Z, Zhang X, Zhou X, et al. Mechanisms of relapse after CD19 CAR T-cell therapy for acute lymphoblastic leukemia and its prevention and treatment strategies. Front Immunol. 2019;10:2664.","journal-title":"Front Immunol"},{"key":"2978_CR41","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/CJI.0000000000000169","volume":"40","author":"J Fischer","year":"2017","unstructured":"Fischer J, Paret C, El Malki K, Alt F, Wingerter A, Neu MA, et al. CD19 isoforms enabling resistance to CART-19 immunotherapy are expressed in B-ALL patients at initial diagnosis. J Immunother. 2017;40:187\u201395.","journal-title":"J Immunother"},{"key":"2978_CR42","doi-asserted-by":"publisher","first-page":"16852","DOI":"10.1073\/pnas.1007896107","volume":"107","author":"FM Uckun","year":"2010","unstructured":"Uckun FM, Goodman P, Ma H, Dibirdik I, Qazi S. CD22 EXON 12 deletion as a pathogenic mechanism of human B-precursor leukemia. Proc Natl Acad Sci USA. 2010;107:16852\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2978_CR43","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nm.3838","volume":"21","author":"AH Long","year":"2015","unstructured":"Long AH, Haso WM, Shern JF, Wanhainen KM, Murgai M, Ingaramo M, et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med. 2015;21:581\u201390.","journal-title":"Nat Med"},{"key":"2978_CR44","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.trecan.2025.08.014","volume":"11","author":"KP Mueller","year":"2025","unstructured":"Mueller KP, Grenier JM, Weber EW. CAR T cell persistence in cancer. Trends cancer. 2025;11:1005\u201318.","journal-title":"Trends cancer"},{"key":"2978_CR45","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1111\/bjh.15195","volume":"181","author":"S Li","year":"2018","unstructured":"Li S, Zhang J, Wang M, Fu G, Li Y, Pei L, et al. Treatment of acute lymphoblastic leukaemia with the second generation of CD19 CAR-T containing either CD28 or 4-1BB. Br J Haematol. 2018;181:360\u201371.","journal-title":"Br J Haematol"},{"key":"2978_CR46","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1172\/JCI85309","volume":"126","author":"CJ Turtle","year":"2016","unstructured":"Turtle CJ, Hanafi LA, Berger C, Gooley TA, Cherian S, Hudecek M, et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J Clin Invest. 2016;126:2123\u201338.","journal-title":"J Clin Invest"},{"key":"2978_CR47","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1158\/2326-6066.CIR-13-0006","volume":"1","author":"MV Maus","year":"2013","unstructured":"Maus MV, Haas AR, Beatty GL, Albelda SM, Levine BL, Liu X, et al. T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer Immunol Res. 2013;1:26\u201331.","journal-title":"Cancer Immunol Res"},{"key":"2978_CR48","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41571-021-00476-2","volume":"18","author":"DL Wagner","year":"2021","unstructured":"Wagner DL, Fritsche E, Pulsipher MA, Ahmed N, Hamieh M, Hegde M, et al. Immunogenicity of CAR T cells in cancer therapy. Nat Rev Clin Oncol. 2021;18:379\u201393.","journal-title":"Nat Rev Clin Oncol"},{"key":"2978_CR49","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa1709919","volume":"378","author":"JH Park","year":"2018","unstructured":"Park JH, Rivi\u00e8re I, Gonen M, Wang X, S\u00e9n\u00e9chal B, Curran KJ, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 2018;378:449\u201359.","journal-title":"N Engl J Med"},{"key":"2978_CR50","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378:439\u201348.","journal-title":"N Engl J Med"},{"key":"2978_CR51","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","volume":"24","author":"JA Fraietta","year":"2018","unstructured":"Fraietta JA, Lacey SF, Orlando EJ, Pruteanu-Malinici I, Gohil M, Lundh S, et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med. 2018;24:563\u201371.","journal-title":"Nat Med"},{"key":"2978_CR52","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.878209","volume":"13","author":"G L\u00f3pez-Cantillo","year":"2022","unstructured":"L\u00f3pez-Cantillo G, Urue\u00f1a C, Camacho BA, Ram\u00edrez-Segura C. CAR-T cell performance: how to improve their persistence? Front Immunol. 2022;13:878209.","journal-title":"Front Immunol"},{"key":"2978_CR53","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1038\/nature05690","volume":"446","author":"CG Mullighan","year":"2007","unstructured":"Mullighan CG, Goorha S, Radtke I, Miller CB, Coustan-Smith E, Dalton JD, et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature. 2007;446:758\u201364.","journal-title":"Nature"},{"key":"2978_CR54","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1038\/leu.2009.135","volume":"23","author":"J Familiades","year":"2009","unstructured":"Familiades J, Bousquet M, Lafage-Pochitaloff M, B\u00e9n\u00e9 MC, Beldjord K, De Vos J, et al. PAX5 mutations occur frequently in adult B-cell progenitor acute lymphoblastic leukemia and PAX5 haploinsufficiency is associated with BCR-ABL1 and TCF3-PBX1 fusion genes: a GRAALL study. Leukemia. 2009;23:1989\u201398.","journal-title":"Leukemia"},{"key":"2978_CR55","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1038\/ng.2754","volume":"45","author":"S Shah","year":"2013","unstructured":"Shah S, Schrader KA, Waanders E, Timms AE, Vijai J, Miething C, et al. A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia. Nat Genet. 2013;45:1226\u201331.","journal-title":"Nat Genet"},{"key":"2978_CR56","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1182\/blood-2018-10-882142","volume":"133","author":"M Passet","year":"2019","unstructured":"Passet M, Boissel N, Sigaux F, Saillard C, Bargetzi M, Ba I, et al. PAX5 P80R mutation identifies a novel subtype of B-cell precursor acute lymphoblastic leukemia with favorable outcome. Blood. 2019;133:280\u20134.","journal-title":"Blood"},{"key":"2978_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12320","volume":"7","author":"E Jacoby","year":"2016","unstructured":"Jacoby E, Nguyen SM, Fountaine TJ, Welp K, Gryder B, Qin H, et al. CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity. Nat Commun. 2016;7:12320.","journal-title":"Nat Commun"},{"key":"2978_CR58","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/nature21076","volume":"542","author":"LN Chan","year":"2017","unstructured":"Chan LN, Chen Z, Braas D, Lee JW, Xiao G, Geng H, et al. Metabolic gatekeeper function of B-lymphoid transcription factors. Nature. 2017;542:479\u201383.","journal-title":"Nature"},{"key":"2978_CR59","volume":"28","author":"M Liang","year":"2021","unstructured":"Liang M, Gong D, Wang L, Liang X, Meng J, Huang W, et al. PAX5 haploinsufficiency induced CD8+ T cells dysfunction or exhaustion by high expression of immune inhibitory-related molecules. Cancer Treat Res Commun. 2021;28:100437.","journal-title":"Cancer Treat Res Commun"},{"key":"2978_CR60","doi-asserted-by":"crossref","unstructured":"Zhang S, Chen X, Jin E, Wang A, Chen T, Zhang X, et al. The GSA Family in 2025: A Broadened Sharing Platform for Multi-omics and Multimodal Data. Genom Proteom Bioinform 2025;23:qzaf072.","DOI":"10.1093\/gpbjnl\/qzaf072"},{"key":"2978_CR61","unstructured":"CNCB-NGDC Members and Partners. Database Resources of the National Genomics Data Center, China National Center for Bioinformation in 2025. Nucleic Acids Res. 2025;53:D30\u2013D44."}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02978-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02978-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02978-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:08:04Z","timestamp":1785521284000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02978-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":61,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["2978"],"URL":"https:\/\/doi.org\/10.1038\/s41375-026-02978-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7751632\/v1","asserted-by":"object"}]},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"assertion":[{"value":"30 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In this article the affiliations had the wrong order have been updated.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"This study was performed in accordance with the Declaration of Helsinki and written informed consent was obtained from each participant. Ethical approval was obtained from the Institutional Review Board of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology. The clinical trial was registered in the Chinese Clinical Trial Registry with the number ChiCTR-OPN-16008526.","order":2,"name":"Ethics","label":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}]}}